MAPT and sporadic Creutzfeldt-Jakob disease: Articles that: (1) are addressed to improve the diagnosis of dementia by means of CSF biomarkers; (2) include patients afflicted with DLB, FTLD, VaD, or CJD. Mixed groups of dementia are excluded; (3) include measures of T-tau and/or p-tau; (4) perform meta-analyses of at least four studies; (5) have more than three patients per diagnostic group; (6) when two studies had overlapping samples, the one with biggest sample was chosen; (7) regarding CJD, studies were included when majority of patients were sporadic CJD